Supplementary Table S1. Number of patients who developed drug side reactions with IL-1 antagonists.

Side effects ((number of patients (%))	Anakinra (n=94)	Canakimumab (n=16)
Anaphylaxis	2 (2,1)	-
Injection site reactions	22 (23,4)	4 (25)
Neutropenia	4 (4,2)	-
Weight gain	8 (8,4)	6 (37,5)
Liver function test abnormality	3 (3,19)	1 (6,25)
Rash	12 (12,76)	-

Supplementary Table S2. Median ADDI scores of study groups.

	ADDI before IL1 antagonist treatment (median (IQR))	ADDI after IL1 antagonist treatment (median (IQR))
Patients without any damage (n=65)	0 (0)	0 (0)
Patients with pre-existing damage* (n=38)	4 (4)	4 (4)
Patients with *de novo* damage (n=2)	0 (0)	1,5 (1)
Patients with increasing damage (n=5)	2 (2)	4 (3)

*Damage is not progressed after IL-1 antagonist treatment in this group

Supplementary Table S3. Distribution of ADDI parameters in study groups.

	Patients with pre-existing damage (n=39)	Patients with increasing damage(n=5)		Patients with de novo damage (n=2)	
		Pre IL-1A	Post IL1A	Pre IL1A	Post IL1A
Amyloidosis	23	4	1	0	1
Non amyloid proteinuria	18	0	1	0	0
Renal insufficiency				0	
Moderate	6	1	0		1
Severe	5	0	0		0
Musculoskeletal complications				0	
Joint restriction	9	1	3		1
Osteoporosis	12	0	1		1
Muscular pain	23	6	6		3
Infertility	4	2	2	0	1
Amenorrhea	0	0	0	0	0
Serosal scarring	1	0	0	0	0

Supplementary Table S4. Number of patients with higher acute phase protein levels in study groups.

	Patients with persistent inflammation (n)	Patients without persistent inflammation (n)	Total
Pre-existing damage	19	20	39
Increased damage	4	1	5
De novo damage	2	0	2